US14159C1036 - Common Stock
CARDIO DIAGNOSTICS HOLDINGS
NASDAQ:CDIO (9/27/2023, 7:16:53 PM)
After market: 0.368 +0 (+0.38%)0.3666
-0.03 (-8.12%)
Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois and currently employs 7 full-time employees. The company went IPO on 2021-11-23. The firm is engaged in the development and commercialization of artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company enables prevention, early detection and assists in the treatment of cardiovascular disease. The firm's Epi+Gen CHD, is a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. Its second product, PrecisionCHD, is an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Its Epi+Gen CHD and PrecisionCHD tests are categorized as laboratory-developed tests (LDTs), which does not require premarket authorization or other Food and Drug Administration (FDA) clearance or approval. The company serves a range of patients, clinicians, hospitals/health systems, employers and payors.
CARDIO DIAGNOSTICS HOLDINGS
311 W. Superior Street, Suite 444
Chicago ILLINOIS
P: 18552269991.0
Employees: 7
Here you can normally see the latest stock twits on CDIO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: